Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market
March 22, 2024 10:14 ET | Spherix Global Insights
Exton, Pennsylvania, March 22, 2024 (GLOBE NEWSWIRE) -- The end of 2023 introduced several new treatment options for patients suffering from ulcerative colitis (UC). Among them is Eli Lilly’s Omvoh...
Mullen Emphasizes Focus on Commercial Vehicle Segment with First Mover Advantage Across Class 1 and 3 Electric Cargo Vans and Trucks
February 26, 2024 10:00 ET | Mullen Automotive, Inc.
Company in full commercial EV production with Class 1 and Class 3 vehicles; Bollinger Motors focused on Class 4-6 vehicles with Class 4 production starting in second half 2024   Company achieves...
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
December 26, 2023 07:13 ET | Rayzebio, Inc.
Transaction Brings RayzeBio’s Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb’s Leading Oncology...
BMS Attributes Sotyk
BMS Attributes Sotyktu Falling Short of Growth Expectations to Access, but Recent Spherix Global Insights’ Data Suggest Safety Concerns Are More of a Barrier to Increased Uptake
December 07, 2023 12:01 ET | Spherix Global Insights
Exton, PA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- While access took the forefront of BMS’ response to Sotyktu (deucravacitinib) not meeting growth expectations during the company’s Q3 earnings call,...
Eli Lilly's Olumiant
Eli Lilly's Olumiant and Pfizer's Litfulo Strengthen Alopecia Areata Arsenal, Yet Resounding Opportunity for JAK Expansion and New Assets in Development Remain
November 15, 2023 11:22 ET | Spherix Global Insights
Exton, Pennsylvania, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Spherix Global Insights has been monitoring the alopecia areata (AA) market for the past four years and has found that the entry of JAK...
An Old Dog with a Ne
An Old Dog with a New Trick… Ellodi’s APT-1011 Promises EoE Patients a Convenient and Potent Treatment Alternative
August 15, 2023 15:40 ET | Spherix Global Insights
Exton, Pennsylvania, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Since launching in May 2022, Sanofi/Regeneron’s Dupixent has been well received by gastroenterologists and allergists as an advancement for...
Immatics Final logo (R)_white_background.png
Immatics gibt $35 Millionen Kapitalbeteiligung von Bristol Myers Squibb bekannt
July 24, 2023 07:00 ET | Immatics N.V.
Tübingen, Deutschland und Houston, Texas, 24. Juli 2023 – Immatics N.V. (NASDAQ: IMTX, „Immatics“), ein Unternehmen, das sich auf die Entwicklung und Herstellung von T-Zell-Immuntherapien für die...
Immatics Final logo (R)_white_background.png
Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
July 24, 2023 07:00 ET |
Tuebingen, Germany and Houston, TX, July 24, 2023 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting...
Immatics Final logo (R)_white_background.png
Immatics veröffentlicht klinisches Daten-Update aus laufender Phase-1b-Zelltherapie-Studie mit ACTengine® IMA203 TCR-T-Monotherapie in Kohorte A gegen die Zielstruktur PRAME
May 02, 2023 07:00 ET | Immatics N.V.
Live-Webcast am Dienstag, den 2. Mai, um 14:30 Uhr MESZ Update umfasst Daten von 11 stark vorbehandelten Patienten nach Letztlinientherapie in der Phase-1b-Dosisexpansionskohorte A, die mit der...
Immatics Final logo (R)_white_background.png
Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME
May 02, 2023 07:00 ET |
Company to host conference call today, May 2, at 8:30 am EDT / 2:30 pm CEST Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203...